$CELG Company News Bull rolls on, but opportunities

New Post Public Reply Private Reply Replies (0) Message Board

Jul 14, 2014 at 10:40 AM

$CELG Company News

Bull rolls on, but opportunities start to dwindle 1:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 2:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 1:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 7:27 a.m. July 9, 2014 - Ciara Linnane
S&P, Dow rattle cage on uncharted territory 11:20 a.m. July 1, 2014 - Michael Ashbaugh
S&P, Dow rattle cage on uncharted territory 10:54 a.m. July 1, 2014 - Michael Ashbaugh
Celgene's fourth stock split is a hit with investors as shares climb 1:02 p.m. June 19, 2014 - Russ Britt
Celgene shareholders approve 2-for-1 stock split 8:57 a.m. June 19, 2014 - Ciara Linnane
Celgene to increase buyback program to 1.15 bln shares from 575 mln 8:52 a.m. June 19, 2014 - Ciara Linnane
Celgene shareholders approve 2-for-1 stock split 8:51 a.m. June 19, 2014 - Ciara Linnane
Celgene drops 1.9%, among worst S&P 500 losers 9:32 a.m. May 29, 2014 - Sue Chang
Higher rates are coming — here’s how you prepare 8:38 a.m. May 12, 2014 - Jeff Reeves
Wall Street up for second day on earnings cheer; biotechs rebound: Stock market live blog recap 4:03 p.m. April 29, 2014 - blogs.marketwatch.com
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Sue Chang
What ‘Game of Thrones’ can teach you about money 8:30 a.m. April 5, 2014 - Wallace Witkowski
Biotechs, bonds and more from the 'tempest in a microsecond' 8:32 a.m. April 2, 2014 - Shawn Langlois
Play-it-safe stock investors may take some risk on jobs 8:31 a.m. March 30, 2014 - Wallace Witkowski
Nasdaq pullback rife with opportunity 2:07 p.m. March 25, 2014 - The Trading Deck
44 stocks on takeover target radar: Morgan Stanley 12:48 p.m. March 25, 2014 - blogs.marketwatch.com
Biotech comeback stalls as Wall Street starts to worry 12:45 p.m. March 25, 2014 - Russ Britt

3 Biotech Stocks That Belong in Your Portfolio 4:45 a.m. Today - InvestorPlace.com
A Contrarian's Take 2:07 a.m. July 12, 2014 - Barrons.com
Oncolytics Up on Patient Enrolment Completion - Analyst Blog 3:00 p.m. July 11, 2014 - Zacks.com
Buying The Dip - The Game Plan 11:41 a.m. July 10, 2014 - Seeking Alpha
Celgene's Otezla Disappoints in Ankylosing Spondylitis Study - Analyst Blog 11:30 a.m. July 10, 2014 - Zacks.com
Cramer's Mad Money - The 4 Horsemen Of Biotech Ride On (7/9/14) 6:27 a.m. July 10, 2014 - Seeking Alpha
Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM 6:00 a.m. July 10, 2014 - TheStreet.com
'Fast Money' Recap: Digging Into Oil Prices 5:00 a.m. July 10, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains 7:53 p.m. July 9, 2014 - TheStreet.com
Pluristem Initiates Trial in South Korea - Analyst Blog 6:00 p.m. July 9, 2014 - Zacks.com
3 Drugs Stocks Driving The Industry Higher 1:03 p.m. July 9, 2014 - TheStreet.com
Two Analysts Don't See Celgene's Weak Trial Results As A Huge Setback 11:37 a.m. July 9, 2014 - benzinga.com
Celgene Drug Otezla Fails Trial, But Street Sanguine 10:52 a.m. July 9, 2014 - Investors Business Daily
Celgene Slips; Drug Candidate Fails Phase III Trial Endpoint 8:37 a.m. July 9, 2014 - benzinga.com
Celgene's Phase 3 Study of Arthritis Drug Misses Target 7:51 a.m. July 9, 2014 - The Wall Street Journal Interactive Edition
UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings 7:49 a.m. July 9, 2014 - 247WallSt.com
Otezla fails to hit primary endpoint in Phase 3 label expansion trial 7:28 a.m. July 9, 2014 - Seeking Alpha
AbbVie Raises Offer for Shire 7:22 p.m. July 8, 2014 - The Wall Street Journal Interactive Edition
Alexion Pharma Looks To Life Beyond Its Blockbuster 1:42 p.m. July 8, 2014 - Investors Business Daily
3 Stocks Reiterated As A Buy: BMY, CAT, CELG 12:29 p.m. July 8, 2014 - TheStreet.com

Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis 7:00 a.m. July 9, 2014 - BusinessWire - BZX
Biotech Stocks Highlight -- Research on Celgene, Inovio Pharma, Amgen, and Array BioPharma 6:40 a.m. July 9, 2014 - PR Newswire - PRF
Clinical Trials, Petitions, and Upcoming Earnings Releases - Analyst Notes on Celgene, Covidien, AbbVie, Teva and Thermo Fisher Scientific 5:40 a.m. July 8, 2014 - PR Newswire - PRF
Celgene Corporation to Announce Second Quarter 2014 Results on July 24, 2014 8:31 a.m. July 1, 2014 - BusinessWire - BZX
CORRECTING and REPLACINGCelgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake 2:28 p.m. June 26, 2014 - BusinessWire - BZX
Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before 9:37 a.m. June 26, 2014 - ACCESSWIRE
Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake 8:30 a.m. June 26, 2014 - BusinessWire - BZX
Celgene Stockholders Approve Two-for-One Stock Split 8:30 a.m. June 19, 2014 - BusinessWire - BZX
Results from Phase III Study (AML-001) of VIDAZA® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at EHA 8:58 a.m. June 14, 2014 - BusinessWire - BZX
Studies Presented at 19th European Hematology Association Annual Congress Evaluate Activin Receptor Ligand Trap Programs in Beta-Thalassemia 3:00 a.m. June 14, 2014 - BusinessWire - BZX
Analysis of Health-Related Quality of Life Measures from the MM-020/IFM 07-01 (FIRST®) Trial Presented at EHA Annual Congress 5:44 p.m. June 13, 2014 - BusinessWire - BZX
Critical Alerts For JC Penney, Brown Forman, Schlumberger, Celgene, and DirecTV Technology Released By InvestorsObserver 9:31 a.m. June 11, 2014 - PR Newswire - PRF
Oral OTEZLA® (Apremilast) Showed Long-Term Clinical Benefits in Patients with Active Psoriatic Arthritis 7:30 a.m. June 11, 2014 - BusinessWire - BZX
Oral OTEZLA® (Apremilast) Monotherapy Showed Long-Term Clinical Benefits in DMARD-Naïve Patients with Active Psoriatic Arthritis 7:30 a.m. June 11, 2014 - BusinessWire - BZX
Health Care Sector Equities Coverage -- Research on Neurocrine Biosciences, PDL BioPharma, Celgene, and Array BioPharma 7:50 a.m. June 6, 2014 - PR Newswire - PRF
Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014 9:01 a.m. June 1, 2014 - BusinessWire - BZX
Veracyte, Foundation Medicine and Panacea Global Paving Way in Faster, More Accurate Cancer Diagnostics 9:53 a.m. May 29, 2014 - ACCESSWIRE
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK 5:50 a.m. May 29, 2014 - PR Newswire - PRF
Organizational Changes Strengthen and Expand Celgene Leadership Team 6:00 a.m. May 22, 2014 - BusinessWire - BZX
Marketing Authorizations, Study Results Presentations, FDA Response to Drug Application, and New Messaging Services - Analyst Notes on Johnson & Johnson, Merck, Celgene, Novartis and UnitedHealth 8:41 a.m. May 21, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Indico Breach May Expose Thousands to Identity Theft

Data Breach Unsettles Indico's Operations Well, this is the kind of headache nobody wants on their spreadsheet—the unpleasant fallout from a significant data breach is rocking Indico Data Solutions. When you hear words like 'unauthorized party' and 'exposed sensitive personal information,' it ought to make investors sit up and pay attention. On May 7, 2026, Indico, the...

Zepp Health's Q2 2026 Results: Growth Amid Struggles

Revenue Growth, Yet the Road Is Rocky Buckle up, investors, because Zepp Health Corporation's (NYSE: ZEPP) latest financials are a bit of a mixed salad—there's some good and some bad tossed in. Reporting a revenue of $63.5 million for the second quarter of 2026, the company managed to eke out a 6.9% increase year-over-year. But before you pop the champagne, let's dig a...

Acer's New Monitors: ePaper, Triple Displays & More

Next-Gen Screens: Breakthrough or Bust? So, Acer’s stepping up its game, unveiling an armory of gadgets designed to cement their spot in the tech arena. On the menu today? ePaper displays and enhanced connectivity gizmos that could either tip the scales or sink like a stone. Keep your eyes peeled, though—these updates aren't just another throwaway press release....

BOC Group's Challenger Role Eye-Opener in Gartner Quadrant

Cracking the Challenger Code: BOC Group's Debut Ever heard of BOC Group? If you haven’t, it’s time to pay attention. This Dublin-based outfit just muscled its way into the Challenger Quadrant of the 2026 Gartner Magic Quadrant for Digital Twin of an Organization Platforms. Not bad for its first trip to the dance. When a company crashes the scene like this, eyebrows...

Ivonescimab Shows Strong Survival in Key Lung Cancer Trial

New Frontiers in Lung Cancer Treatment Well, here's a story that rattles the cage in the oncology world. The name of the game is ivonescimab, Akeso’s latest move as they toss their hat into the already crowded yet pivotal lung cancer treatment ring. This isn't just some side hustle—they've got Phase III data pointin' straight north, figuratively casting a shadow over...

Volato Group Faces Merger Scrutiny Amid SOAR Deal

Unraveling the Volato Merger Drama Boy, the plot thickens with Volato Group, Inc. (SOAR), and it ain’t the first time we’ve seen this kind of shuffle in the market. Now, Volato’s got itself tangled up with Alignment Engine Inc. through a proposed merger. Sounds routine at first; we all know mergers are part of the corporate game. But here's the twist—shareholders...

Kareem's Lebanese Kitchen: A Culinary Tribute to Maryland

Embracing Tradition with a Modern Twist Well, here's to new beginnings wrapped in old flavors, folks. September 1, 2026, marks the arrival of Kareem's Lebanese Kitchen at Rio Lakefront in Gaithersburg, Maryland. It's where the Mediterranean meets the Chesapeake in an unexpected culinary celebration. Chef Rachid Eido's Legacy Third-generation Lebanese Chef Rachid Eido is...

RealityMine Appoints CPO Amidst Strong Growth Momentum

Pushing the Boundaries of Behavioral Data When a company like RealityMine posts a whopping 75% year-over-year revenue bump, you know they're not here to mess around. Enter Soumya Bijjal, a seasoned pro stepping in as their inaugural Chief Product Officer. This isn't just about adding to the C-suite boys' club; it's about locking in on a goldmine of behavioral data that's...

Kroger's Strategic Shift: Ibbotson's Bold New Charge

Kroger Welcomes a Seasoned Retail Veteran Change often arrives with the dawn of new leadership. As Kroger takes a page from the playbook of large-scale retail transformation, they've enlisted Mark Ibbotson. Effective September 14, Ibbotson will step in as Executive Vice President and Chief Store Operations Officer. It's a roll of the dice that could either accelerate...

Innventure Faces Class Action Over Alleged Deception

Unpacking the Innventure Debacle Innventure, Inc. (NASDAQ:INV) seems to have landed itself in hot water, and not the relaxing kind. The revelation that its grand AI data center project in Ontario might never have existed has stirred up quite a storm among shareholders. This isn't just some run-of-the-mill oversight. We're talking about allegations of concocted stories...